Top Industry News

Roche has agreed to acquire Poseida Therapeutics, a San Diego, California-based clinical-stage cell- and gene-therapy company developing treatments for cancer, autoimmune, and rare diseases, in a $1.5-billion deal ($1.0 billion…

The latest from CDMOs, CMOs, and suppliers featuring Resilience, Sartorius, Agilent, Cambrex, Evotec, Hovione and Samabriva.   Biologics Manufacturing * Resilience Names New CEO * Sartorius Opens New Center for Bioprocess Innovation * Samabriva…

A roundup of news from Novo Nordisk, Novavax, Coherus BioSciences and Intas Pharmaceuticals. Highlights below.   General * Novo Nordisk Investing $411 M in New Quality Control Facility Mfg News * Novo Nordisk To…

Amcor, a Zurich, Switzerland-based provider of packaging for the pharmaceutical, food, beverage, and other markets, has agreed to acquire Berry Global, an Evansville, Indiana-based provider of packaging for various markets,…

Grifols, a Barcelona, Spain-headquartered healthcare company and manufacturer of plasma-derived medicines, has turned down a potential offer of EUR 6.45 billion ($6.76 billion) by Brookfield, a Toronto, Canada-based private equity…

Novartis has acquired Kate Therapeutics, a San Diego, California-based gene-therapy company specializing in treating genetically defined neuromuscular diseases, in a $1.1-billion deal (undisclosed upfront payment and additional milestone payments). Kate…

The latest from CDMOs, CMOs, and suppliers featuring Samsung Biologics, Fujifilm Diosynth Biotechnologies, Vetter, Pii, and Evotec.   Biologics Manufacturing * Samsung Biologics Signs $668-M Contract Mfg Deal* Fujifilm Diosynth Biotechnologies Completes…

A roundup of manufacturing news from Sanofi, Orano Med, and Endo. Highlights below  * Sanofi Investing $42 M To Expand Bioproduction in France* Orano Med Investing $262 M To Expand…

A roundup of news from Pfizer, Amgen, and Novartis. Highlights below.   Appointments * Pfizer Names New Chief Scientific Officer & President, R&D * Amgen Names New Chief Scientific Officer, SVP of Research Partnering *…

AstraZeneca has announced $3.5 billion of capital investment in the US focused on expanding the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of…